AcelRx raises ~$7.5M via registered direct offering of common stock and warrants

TALPHERA, INC.

Sold 748,744 shares, pre-funded warrants for 2,632,898 shares, and common warrants for 4,227,052 shares at $2.22625 combined price.
Gross proceeds ~$7.5M; Cantor Fitzgerald placement agent with 7% fee.
Common warrants exercisable at $2.07 after 6 months, 6-year term, full ratchet anti-dilution with $1.00 floor.
Amended prior warrant held by purchaser to reduce exercise price to $2.07.
Closing expected on or about Dec 29, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.